Pasireotide
Lobular Carcinoma in Situ (LCIS)
NYU Langone Healthprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Lobular Carcinoma in Situ (LCIS) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TAMOXIFEN National Cancer Institute (NCI) | Phase 3 | BB |
Oxybutynin Academic and Community Cancer Research United | Phase 3 | BB |
Letrozole Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Metformin Alliance for Clinical Trials in Oncology | Phase 3 | B |
EXEMESTANE Alliance for Clinical Trials in Oncology | Phase 3 | B |
View all 20 →
Same molecule, other indications
Pasireotide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →